The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
1. A purified polypeptide comprising a fragment of an amino acid sequence of SEQ ID NO: 2536, wherein said fragment comprises 10 or more consecutive amino acids from said amino acid sequence.
2. The purified polypeptide of claim 1 , wherein said fragment comprises 12 or more consecutive amino acids from said amino acid sequence.
3. The purified polypeptide of claim 1 , wherein said fragment comprises 14 or more consecutive amino acids from said amino acid sequence.
4. The purified polypeptide of claim 1 , wherein said fragment comprises 16 or more consecutive amino acids from said amino acid sequence.
5. The purified polypeptide of claim 1 , wherein said fragment comprises 18 or more consecutive amino acids from said amino acid sequence.
6. The purified polypeptide of claim 1 , wherein said fragment comprises 20 or more consecutive amino acids from said amino acid sequence.
7. The purified polypeptide of claim 1 further comprising a pharmaceutically acceptable carrier.
8. The purified polypeptide of claim 1 , wherein the purified polypeptide is immunogenic.